Atherosclerosis is the primary cause of heart attack, stroke, and peripheral artery disease, which collectively account for >30% of all deaths in the US. Multiple studies recognized abnormal cholesterol homeostasis as a risk factor for the development of atherosclerosis. We and others have recently reported on miR-33, a conserved microRNA that is encoded within intron 16 of SREBP-2. The clinical importance of SREBP-2 is revealed in hypercholesterolemic patients treated with statins, which reduce LDL-cholesterol levels by increasing hepatic expression of SREBP-2 and its target the LDL-receptor. Our published and preliminary studies show that physiological targets of miR-33 include ABCA1, a transporter critical for HDL lipidation and reverse cholesterol transport, and ATP8B1, a phospholipid flippase linked to intrahepatic cholestasis. The broad goal of this proposal is to determine the role of miR-33 on cholesterol, bile and lipoprotein homeostasis. We hypothesize that miR-33 controls key aspects of sterol mobilization, bile excretion and HDL metabolism. Importantly, since statins are usually prescribed to hypercholesterolemic patients, and statins induce the expression of miR-33, we speculate that statin-treated patients will have elevated levels of miR-33 and persistent down regulation of ABCA1 and ATP8B1 by miR-33. To address these questions, we propose the following 3 specific aims: 1) Determine the role of miR-33 in hepatic sterol homeostasis in primary hepatocytes and in mice, by measuring the effect of over expression or silencing of miR-33 on lipoprotein secretion and bile excretion; 2) Test the hypothesis that altered macrophage miR-33 expression results in changes in reverse cholesterol transport and atherosclerotic lesion size, by performing experiments in vivo to determine the role of macrophage miR-33 expression on cholesterol -/- mobilization and progression of atherosclerotic lesions in Ldlr mice ; and 3) Test the hypothesis that systemic silencing of miR-33 is atheroprotective in vivo, by characterizing the composition and biological properties of HDL generated following systemic silencing of miR-33, and by evaluating whether anti-miR-33 oligonucleotides synergize with the atheroprotective effects of statins in ApoE*3Leiden W hCETP mice. There are still multiple aspects of cholesterol homeostasis, cholestasis and atherogenesis that remain obscure. Our data suggest that the cholesterol-miR-33 axis modulates key aspects of hepatocyte and macrophage biology. We anticipate that our studies will provide new clues into the complex regulatory networks that control intracellular cholesterol levels, bile excretion and circulating lipoproteins. If our hypothesis is true, miR-33 might be a target for novel therapies to manage dyslipidemias and/or cholestasis.
We propose to characterize miR-33, which defines a novel pathway that controls cholesterol, bile and lipoprotein homeostasis. We hypothesize that miR-33 modulates the expression of key genes involved in different aspects of sterol metabolism. The results of these studies might lead to novel, improved ways to manage patients with hypercholesterolemia and/or patients with cholestasis.
|Kreienkamp, Ray; Billon, Cyrielle; Bedia-Diaz, Gonzalo et al. (2018) Doubled lifespan and patient-like pathologies in progeria mice fed high-fat diet. Aging Cell :e12852|
|Rajamoorthi, Ananthi; Lee, Richard G; Baldán, Ángel (2018) Therapeutic silencing of FSP27 reduces the progression of atherosclerosis in Ldlr-/- mice. Atherosclerosis 275:43-49|
|Price, Nathan L; Singh, Abhishek K; Rotllan, Noemi et al. (2018) Genetic Ablation of miR-33 Increases Food Intake, Enhances Adipose Tissue Expansion, and Promotes Obesity and Insulin Resistance. Cell Rep 22:2133-2145|
|Price, Nathan L; Rotllan, Noemi; Canfrán-Duque, Alberto et al. (2017) Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis. Cell Rep 21:1317-1330|
|Palladino, Elisa N D; Wang, Wen-Yi; Albert, Carolyn J et al. (2017) Peroxisome proliferator-activated receptor-? accelerates ?-chlorofatty acid catabolism. J Lipid Res 58:317-324|
|de Aguiar Vallim, Thomas Q; Lee, Elinor; Merriott, David J et al. (2017) ABCG1 regulates pulmonary surfactant metabolism in mice and men. J Lipid Res 58:941-954|
|Rajamoorthi, Ananthi; Arias, Noemí; Basta, Jeannine et al. (2017) Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate. J Lipid Res 58:2127-2138|
|Langhi, Cédric; Arias, Noemí; Rajamoorthi, Ananthi et al. (2017) Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance. J Lipid Res 58:81-91|
|Baldán, Ángel; de Aguiar Vallim, Thomas Q (2016) miRNAs and High-Density Lipoprotein metabolism. Biochim Biophys Acta 1861:2053-2061|
|Pauta, Montse; Rotllan, Noemi; Fernández-Hernando, Ana et al. (2016) Akt-mediated foxo1 inhibition is required for liver regeneration. Hepatology 63:1660-74|
Showing the most recent 10 out of 26 publications